Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone Palmitate Recurrence Prevention in Schizophrenia
NCT00111189Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Feb 2005
- Primary completion
- Feb 2007
- Modality
- Metabolically Activated Prodrugs
- Countries
- 9
01
Overview
A Phase 3 trial of paliperidone palmitate in schizophrenia, sponsored by Johnson & Johnson. Started Feb 2005; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00111189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111189.